Sinocare(SZ:300298) EBSCN·2025-10-27 06:59Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [5][13]. Core Insights - The company's revenue for the first three quarters of 2025 reached 3.453 billion yuan, a year-on-year increase of 8.52%, while the net profit attributable to shareholders was 211 million yuan, a decline of 17.36% [1]. - In Q3 2025, the company achieved revenue of 1.190 billion yuan, up 13.40% year-on-year, but the net profit attributable to shareholders fell by 47.55% due to a one-time payment of 19 million USD (approximately 136 million yuan) related to a patent settlement with Roche [1][2]. - Excluding the one-time patent fee, the company's underlying profit showed strong growth, with a net profit of 105 million yuan in Q3 2025 [2]. Summary by Sections Revenue and Profitability - The company’s CGM (Continuous Glucose Monitoring) business is a key driver of growth, with strong performance in both domestic and international markets. The company aims to achieve its annual sales target [2]. - The traditional BGM (Blood Glucose Monitoring) business continues to grow steadily in China [2]. Market Position and Strategy - The company has adopted a differentiated competitive strategy, focusing on cost-effective first-generation products and high-end second-generation products. This approach has led to a reduction in losses for domestic operations and gradual improvement in profitability [2]. - The company is making progress in obtaining insurance coverage for its CGM products in Europe and the Middle East, laying the groundwork for future sales growth [2]. Financial Forecasts - The net profit forecast for 2025 has been revised down to 288 million yuan, a 23% decrease from the previous estimate of 374 million yuan. However, the forecasts for 2026 and 2027 remain at 468 million yuan and 564 million yuan, respectively [3][4]. - The report provides a detailed financial summary, including projected revenues and profits for the years 2023 to 2027, indicating a growth trajectory despite short-term challenges [4][9].